GlassScriptPhysician profile
Meredith M Barnett
NPI 1992194526
$2,802.64
in general payments reported to CMS, 2019-2025
35 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $904 · 2022: $1,231 · 2023: $148 · 2024: $317 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648 · Consulting Fee: $20.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.75 |
| Consulting Fee | $20.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $448.78 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $181.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.42 | 2021-2022 | |
| Novo Nordisk INC | $162.50 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.78 | 2021-2025 | Hyqvia, Glassia |
| Novartis Pharmaceuticals Corporation | $146.62 | 2022 | |
| Amgen INC. | $127.49 | 2021-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $112.51 | 2021-2022 | |
| Csl Behring | $106.64 | 2023-2025 | Hizentra |
| Glaxosmithkline, LLC. | $104.65 | 2021-2025 | Nucala |
| Tg Therapeutics, INC. | $96.70 | 2024 | |
| Dexcom, INC. | $88.71 | 2021-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $86.50 | 2021-2022 | |
| Boston Scientific Corporation | $85.38 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Lundbeck LLC | $80.74 | 2023-2025 | Vyepti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $78.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $71.48 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $58.53 | 2021 | |
| Pfizer INC. | $56.84 | 2021-2022 | |
| Genentech USA, INC. | $40.89 | 2023-2024 | Xolair, Ocrevus Zunovo |
| Esperion Therapeutics, INC. | $36.00 | 2021-2023 | Nexletol |
| Eisai INC. | $35.93 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $32.45 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.19 | 2021 | |
| Amarin Pharma, INC. | $29.11 | 2021-2022 | |
| Corcept Therapeutics | $28.70 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.53 | 2022 | |
| Adma Biomanufacturing LLC | $20.43 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.48 | 2023 | Ultomiris |
| Idorsia Pharmaceuticals US INC | $18.02 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.69 | 2021 | |
| Ibsa Pharma INC. | $15.36 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.16 | 2022 | |
| Insulet Corporation | $14.08 | 2022 | |
| Astellas Pharma US INC | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.